AzTrials
AzTrials

Young Onset Asian Diabetes (Under 40 Years)DIARYNCT07452159

Diabetes In Asians at Risk in Youth

An observational study of Young Onset Asian Diabetes (Under 40 Years), run by Singapore General Hospital.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This observational study aims to develop novel contemporary risk factor tools for detecting young onset diabetes (under 40y) in young Asians in Singapore. The investigators aim to recruit 3000 people not currently known to have diabetes, selected across age and Body Mass Index categories, and perform formal diagnostic… Read more about this study

Who is it for?
Ages 21 to 39 yearsHealthy volunteers can take part
What is being tested?
Oral glucose tolerance test and HbA1c, Anthropometric measurements and Body impedance Analysis
Type of treatment
Pill or oral medicine
How many people
3,000 participants
Where
No sites listed yet
Study dates
18 Mar 2026to 2 Jan 2029
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 39 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: Islandwide across Singapore

Who may be able to join

  • Asian/Part Asian ethnicity living in Singapore, not known to have diabetes

Who cannot join

  • Pregnancy women
  • Non-Asian ethnicity
  • On active cancer/steroid therapy
  • Haemoglobinopathies or haemolytic anaemia
  • Previous bariatric surgery
  • Previous partial/total pancreatectomy

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Daphne SL Gardner, BA, BMBCh (Oxon), MRCP (UK) contact

+6563214654

daphne.gardner@singhealth.com.sg

About this study

Official title: Diabetes in Asians at Risk in Youth

This observational study aims to develop novel contemporary risk factor tools for detecting young onset diabetes (under 40y) in young Asians in Singapore. The investigators aim to recruit 3000 people not currently known to have diabetes, selected across age and Body Mass Index categories, and perform formal diagnostic tests for diabetes (oral glucose tolerance test and HbA1c). The participants will also undergo continuous glucose monitoring sensor, keep a food diary, and undergo body composition analysis using bioimpedance analysis, handgrip measurements for muscle strength, and sociobehavioural profiling through download of a curated list of social media interactions. The participants will also have a blood sample retrieved and stored for subsequent comparison between people with normal glucose versus abnormal glucose levels. The whole group will also have another blood sample stored for whole gene analysis.

Read the detailed description

Overarching aim: To improve the case detection rate of T2D in young Singaporeans adults aged 21-40y.

Specific Aim 1: To conduct a case-finding study for T2D and prediabetes through age- and BMI-stratified sampling in a contemporary population of young Singaporean adults aged 21-40y.

Specific Aim 2: To identify novel risk factors and develop a composite score to improve the detection rate for Asian YOD and prediabetes. These include non-traditional predictors such as glucometrics from continuous glucose monitoring (CGM), body composition measures, and socio-behavioural analyses.

Specific Aim 3: To identify the contribution of genomic differences to the risk of Asian Young Onset Diabetes

To fulfil Aim 1 within the first 1 to 2 years, the investigators plan to perform island-wide screening for diabetes or prediabetes amongst people aged 21-40y (n=3000). Recruitment will be stratified firstly by age categories (21-25y, 25-30y, 30-35y, 35-40y), aiming for n=750 per age category, followed by BMI categories of normal, overweight or obese by Asian thresholds (<23kgm2, 23-27.5kg/m2 and >=27.5kg/m2) within each age group. Participants will be recruited through online and print media including social media advertisements, word of mouth and /or referrals. A study poster advert will be posted online and in print, which will then direct participants to a webpage www.thdiary.sg which will explain the study design further and eligibility requirements and additional study details. The partiipants can proceed to register themselves via FORMSG on this webpage and if they meet the criteria they will be directed to CALSG to book an appointment with the study team.

Upon consent and recruitment, the following will be done:

  1. Anthropometric measurements alongside traditional risk factors including blood pressure (BP), and waist-hip-ratio.
  2. Body Impedance Analysis. This is a painless way to measure what the body is made of and involves standing on a special scale and holding onto handles.
  3. Venipuncture will be conducted for an oral glucose tolerance test (OGTT) for 0 min, 1h and 2h glucose readings and HbA1c and storage.
  4. Download of selected social media data (not directly containing personal data or posts) for up to 1 year preceding the visit from facebook, instagram and tiktok.
  5. Continuous glucose monitor (CGM) sensor insertion. On the day of CGM insertion, a pre-insertion questionnaire (using form.sg, DIARY skin reaction form 1 before sensor wear) will be filled in which includes a picture of the site before sensor insertion.
  6. A survey will also be conducted to ascertain sociodemographic (employment, type of residence) and educational status, family history of diabetes and comorbid conditions (if any), the individual's dietary intake, physical activity levels, and health-seeking behaviour. This survey will also include a section to fill in their average daily step count for 7/30 days. The participant will be guided to look for their step count data over 7 or 30 days (depending on what is available) from their smartphone activity tracker (this includes Apple Health, Samsung Health or Google Fit or any other activity tracker). This information will then be entered into the survey form on form.sg. No screenshots or data export is required.
  7. Handgrip measurements
  8. Second and third venipunctures for second part of OGTT.
  9. Collection of dietary data via a digital food log

In Aim 2, the investigators aim to identify novel contemporary risk markers associated with T2D or prediabetes in young adults. This aim will not require another study visit from participants. Stored samples from Aim 1 baseline OGTT venipuncture will be used as well as the data retrieved from the study procedures in aim 1. Those who are diagnosed with T2D and prediabetes (estimated n=200 each), together with a normoglycaemic group (n=200) from Aim 1 will have the following done to enable diabetes subtyping: lipids, C-peptide, Insulin levels, Glutamic Acid Decarboxylase (GAD), Islet Antigen 2 (IA-2) Antibodies (Ab) and Zinc Transport 8 (ZnT8) Ab.

A composite score will then be developed for the diagnosis of prediabetes and diabetes. The dataset will be split into development and validation sets. Logistic regression modelling and Receiver Operating Characteristics (ROC) curve analysis will be employed to develop a composite score in identifying people with T2D or prediabetes, based on the sample with 200 newly diagnosed T2D, 200 prediabetes and 200 normoglycaemic participants. With the development set, two models will be fitted to predict a subject belongs to T2D, prediabetes or normoglycaemia: (a) candidate predictor variables of all abovementioned indicators and their derivatives, including sociodemographic, family history of diabetes and comorbid conditions, dietary intake, physical activity levels, body composition metrics, health-seeking behaviours, as well as CGM biomarkers, and (b) candidate predictor variables of all these variables except those extracted / derived from CGM. Variable selection methods will be employed to determine final models with optimal predictability, parsimony and model fit indices. Two composite scores, including and not including CGM biomarkers, will then be defined by the final selected models.

To fulfil aim 3, stored blood from participants will be used in ongoing large scale genomic studies such as the National Precision Medicine's Phase 3 programme. In this program, participants will have whole genome sequencing performed under research, with a cluster specific centralized genomics team made up of clinical geneticists, bioinformaticians, variant curators, and genetic counsellors available to process the genetic specimens end to end (genomics innovation hub). This would involve curating genes relevant to the disease subtype, in this case, diabetes, but also returning incidental findings that are Tier 1 American College of Medical Genetics and Genomics (ACMG) conditions. VCF files from the participants of this study will be returned to this study team so that further research can be done to determine if genomic information can further help risk stratify Asian YOD.

Being tested
Oral glucose tolerance test and HbA1c, Anthropometric measurements, Body impedance Analysis, Handgrip measurement, Continuous glucose monitoring
Keywords
Young onset diabetes, Asian, Risk factors, contemporary

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Oral glucose tolerance test and HbA1cDiagnostic test

    Following overnight fasting for 8 hours

  • Anthropometric measurementsOther

    Body Mass Index, Waist-Hip ratio, Blood pressure

  • Body impedance AnalysisDiagnostic test

    Body composition analysis

  • Handgrip measurementDiagnostic test

    Handgrip strength measured using Jamar Dynanometer

  • Continuous glucose monitoringDiagnostic test

    Use of Retrospective continuous glucose monitoring sensor (Freestyle Libre Pro IQ)

  • Food diary recording over days 2 and 3 of continuous glucose monitoringOther

    Including written food records and photographs for all food and drink intake

  • SurveyOther

    Retrieval of sociodemographic details, family history of diabetes and comorbid conditions, information on dietary intake, physical activity levels, and health seeking behaviour. This includes average daily step count for 7/30 days.

  • Skin reaction informationOther

    Form to feedback on any sensor skin reactions

  • Download of social media dataOther

    This will involve a highly curated list of information to be retrieved from Facebook, Instagram and TikTok to enable AI-led sociobehavioural profiling. This will not retrieve any information on posts, photos, likes, comments, reactions or any item that will express intent.

  • Whole genome sequencingDiagnostic test

    Whole blood sample will be retrieved and stored before being sent for whole genome sequencing at a later stage.

Study groups in NCT07452159
Study groupRoleWhat they receive
Singaporeans of Asian ethnicity under 40 yearsNot previously known to have diabetes
Receives: Diagnostic Test: Oral glucose tolerance test and HbA1c; Other: Anthropometric measurements; Diagnostic Test: Body impedance Analysis; Diagnostic Test: Handgrip measurement; Diagnostic Test: Continuous glucose monitoring; Other: Food diary recording over days 2 and 3 of continuous glucose monitoring; Other: Survey; Other: Skin reaction information; Other: Download of social media data; Diagnostic Test: Whole genome sequencing

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Diagnosis of diabetes

    Fasting glucose >/=7mmol/l or 2-hour glucose >/=11.1 mmol/l on oral glucose tolerance test or HbA1c >/=7%.

    Measured: Baseline

Secondary outcomes (1)
  1. Diagnosis of pre-diabetes

    Fasting glucose >/=5.7mmol/l or 2-hour glucose >/=7,8 mmol/l on oral glucose tolerance test or HbA1c >/= 5.7%.

    Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Mar 2026
  2. Study start18 Mar 2026 (estimated)
  3. Primary completion2 Jan 2029 (estimated)
  4. Study completion2 Jan 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
3,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07452159
Sponsor's protocol ID
DIARY : CIRB 2025-0719
Other IDs
Tanoto Foundation MRF
Acronym
DIARY
Status last verified
Feb 2026
First submitted
1 Dec 2025
Last updated
5 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: This is an observational study, only aggregated data will be provided. In addition, there is a part of the study that retrieves information social media activity. There is a potential that individual level data can lead to sensitive personal information being revealed.

Publications

  • Zahalka SJ, Galindo RJ, Shah VN, Low Wang CC. Continuous Glucose Monitoring for Prediabetes: What Are the Best Metrics? J Diabetes Sci Technol. 2024 Jul;18(4):835-846. doi: 10.1177/19322968241242487. Epub 2024 Apr 17.

    PubMed 38629784
  • Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev. 2002 Aug;3(3):141-6. doi: 10.1046/j.1467-789x.2002.00065.x.

    PubMed 12164465
  • Kuang M, Lu S, Yang R, Chen H, Zhang S, Sheng G, Zou Y. Association of predicted fat mass and lean body mass with diabetes: a longitudinal cohort study in an Asian population. Front Nutr. 2023 May 9;10:1093438. doi: 10.3389/fnut.2023.1093438. eCollection 2023.

    PubMed 37229472
  • Yeung RO, Zhang Y, Luk A, Yang W, Sobrepena L, Yoon KH, Aravind SR, Sheu W, Nguyen TK, Ozaki R, Deerochanawong C, Tsang CC, Chan WB, Hong EG, Do TQ, Cheung Y, Brown N, Goh SY, Ma RC, Mukhopadhyay M, Ojha AK, Chakraborty S, Kong AP, Lau W, Jia W, Li W, Guo X, Bian R, Weng J, Ji L, Reyes-dela Rosa M, Toledo RM, Himathongkam T, Yoo SJ, Chow CC, Ho LL, Chuang LM, Tutino G, Tong PC, So WY, Wolthers T, Ko G, Lyubomirsky G, Chan JC. Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort. Lancet Diabetes Endocrinol. 2014 Dec;2(12):935-43. doi: 10.1016/S2213-8587(14)70137-8. Epub 2014 Jul 28.

    PubMed 25081582
  • Rama Chandran S, Sng GGR, Wong CYH, Ang WM, Gardner D. Continuous Glucose Monitoring Metrics in Asians Without Diabetes: Differentiating Prediabetes From Normoglycemia. J Diabetes Sci Technol. 2025 Oct 21:19322968251384682. doi: 10.1177/19322968251384682. Online ahead of print.

    PubMed 41117210
  • Tan JK, Salim NNM, Lim GH, Chia SY, Thumboo J, Bee YM. Trends in diabetes-related complications in Singapore, 2013-2020: A registry-based study. PLoS One. 2022 Oct 11;17(10):e0275920. doi: 10.1371/journal.pone.0275920. eCollection 2022.

    PubMed 36219616

Questions about this trial

What is this clinical trial studying?

An observational study of Young Onset Asian Diabetes (Under 40 Years), run by Singapore General Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 5 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Daphne SL Gardner, BA, BMBCh (Oxon), MRCP (UK) (+6563214654, daphne.gardner@singhealth.com.sg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Diagnosis of diabetes (time frame: Baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07452159, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in